About Us

At Viela, we are working to redefine the treatment of autoimmune disease by focusing on pathways shared across various diseases. We believe this approach–which targets the underlying molecular pathogenesis of a disease– may enable us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple diseases with each product candidate. Our pipeline includes novel therapies for neuromyelitis optica spectrum disorder, kidney transplant rejection and Sjögren’s syndrome.

Learn More